The use of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) as a pathway-specific biomarker with AZD8186, a PI3Kß/Î´ inhibitor.

Maynard, Juliana; Emmas, Sally-Ann; Blé, Francois-Xavier; Barjat, Hervé; Lawrie, Emily; Hancox, Urs; Oakes, Deborah; Polanska, Urszula M; Barry, Simon T

Maynard, Juliana; Emmas, Sally-Ann; Blé, Francois-Xavier; Barjat, Hervé; Lawrie, Emily; Hancox, Urs; Oakes, Deborah; Polanska, Urszula M; Barry, Simon T.

Afiliación

Maynard J; Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, SK10 4TG, UK. Juliana.maynard@alderleyimaging.com.
Emmas SA; Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, SK10 4TG, UK.
Blé FX; Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, SK10 4TG, UK.
Barjat H; Personalised Healthcare and Biomarkers, AstraZeneca, Alderley Park, SK10 4TG, UK.
Lawrie E; Drug Safety and Metabolism IMED, AstraZeneca, Alderley Park, SK10 4TG, UK.
Hancox U; Oncology IMED, AstraZeneca, Alderley Park, SK10 4TG, UK.
Oakes D; Oncology IMED, AstraZeneca, Alderley Park, SK10 4TG, UK.
Polanska UM; Oncology IMED, AstraZeneca, Alderley Park, SK10 4TG, UK.
Barry ST; Oncology IMED, AstraZeneca, Alderley Park, SK10 4TG, UK.

EJNMMI Res ; 6(1): 62, 2016 Dec.

Article en En | MEDLINE | ID: mdl-27515445

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: EJNMMI Res Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido